Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta-analysis.

ABSTRACT:

Background and aim

Ulcerative colitis (UC) causes chronic inflammation in the digestive tract, leading to abdominal pain and diarrhea. Adalimumab, a monoclonal antibody, is used to treat moderate to severe cases. This review and meta-analysis evaluated adalimumab's effectiveness for severe UC, considering patient age, disease duration, and gender.

Methods

This study was designed as a systematic review and a meta-analysis. Articles were searched in PubMed, Scopus, and Web of Science databases based on the keywords of adalimumab and UC. The titles, the abstracts, and, if necessary, the full texts of the articles were read. Then for further review, the full texts of the related articles were carefully examined, and the final articles were selected. Seventy-eight articles were s

SUBMITTER: Azadbakht S 

PROVIDER: S-EPMC11258201 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature